Posted by Michael Wonder on 20 Aug 2024
China’s NMPA approves Padcev (enfortumab vedotin) for treatment of locally advanced or metastatic urothelial cancer
20 August 2024 - Approval based on the global EV-301 and China EV-203 trials, where enfortumab vedotin significantly improved overall survival (OS) and objective response rate respectively in patients following prior treatment with platinum-based chemotherapy and PD-1/L1 inhibitors.
Astellas today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has approved Padcev (enfortumab vedotin) for the treatment of adult patients with locally advanced or metastatic urothelial cancer after prior treatment with platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitors.
